TrialArthritis research & therapy2019

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.

Min-Chan Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.